Key Points
- Polaryx Therapeutics CEO Alex Keun Mo Yang bought 88,453 shares on May 27 at an average price of $4.07 each, spending about $360,004. After the purchase, he directly owned 24.23 million shares valued at roughly $98.6 million.
- The trade increased his ownership by 0.37% and was disclosed in a filing with the SEC.
- PLYX shares were trading at $3.05 on Friday, with a 52-week range of $2.07 to $48.91 and a 50-day moving average of $5.06. The company recently reported a quarterly loss of $0.03 per share, and analysts currently have a consensus rating of Hold with a $10 target price.
Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) CEO Alex Keun Mo Yang purchased 88,453 shares of the firm's stock in a transaction dated Wednesday, May 27th. The stock was acquired at an average price of $4.07 per share, with a total value of $360,003.71. Following the purchase, the chief executive officer directly owned 24,233,249 shares of the company's stock, valued at approximately $98,629,323.43. The trade was a 0.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Polaryx Therapeutics Price Performance
PLYX stock opened at $3.05 on Friday. Polaryx Therapeutics, Inc. has a 1-year low of $2.07 and a 1-year high of $48.91. The business has a fifty day simple moving average of $5.06.
Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.03) earnings per share for the quarter.
Wall Street Analysts Forecast Growth
PLYX has been the subject of several recent analyst reports. Weiss Ratings initiated coverage on Polaryx Therapeutics in a research note on Friday, April 24th. They issued a "sell (e-)" rating for the company. Maxim Group initiated coverage on Polaryx Therapeutics in a research note on Friday, February 27th. They issued a "buy" rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Polaryx Therapeutics presently has a consensus rating of "Hold" and an average target price of $10.00.
Read Our Latest Stock Analysis on Polaryx Therapeutics
About Polaryx Therapeutics
(
Get Free Report)
We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
